Paradox Immunotherapeutics Gains $10 Million Investment from SymBiosis to Propel Treatments for Protein Misfolding Disorders

On February 25, 2025, Paradox Immunotherapeutics, a Toronto-based pharmaceutical company dedicated to developing innovative antibody therapies for protein misfolding diseases, announced a significant $10 million financing round led by SymBiosis, an investment firm specializing in biotherapeutics for serious illnesses. This funding is aimed at advancing Paradox's therapeutic pipeline, which targets diseases with considerable unmet medical needs.

Paradox employs a cutting-edge platform for lead identification and validation capable of developing antibodies that specifically target misfolded proteins, ensuring that healthy proteins remain unscathed. This precision approach is crucial for addressing conditions such as immunoglobulin light chain amyloidosis (AL amyloidosis) and leukocyte chemotactic factor 2 amyloidosis (LECT2). AL amyloidosis is a complication often associated with multiple myeloma that can result in severe complications, including heart, kidney, and liver failure. LECT2, on the other hand, is frequently overlooked, leading to chronic kidney disease and eventual kidney failure.

Dr. Natalie Galant, Co-Founder and CEO of Paradox Immunotherapeutics, expressed enthusiasm about the funding, stating that it will allow the company to accelerate its development efforts, addressing urgent medical needs in a market rife with ineffective treatments. The partnership with SymBiosis, which shares Paradox's vision for innovative therapies, brings both financial support and strategic guidance to help realize this potential.

Chidozie Ugwumba, Managing Partner of SymBiosis, emphasized the complexity associated with developing effective therapies for protein misfolding diseases and highlighted the enormous possibilities presented by Paradox’s unique approach and its promising pipeline. He expressed optimism about the opportunity to change treatment paradigms for multiple ailments through Paradox's potential best-in-class and first-in-class therapies.

In conjunction with the financing, Sandy Zweifach from SymBiosis has expanded Paradox’s leadership team by joining as an independent director and Executive Chairman.

Paradox Immunotherapeutics has garnered validation for its innovative strategies, achieving recognition in various industry competitions and programs, including being a finalist in J.P. Morgan’s Life Sciences Innovation Summit and a winner at the BIO Emerging Company Start-Up Stadium. Their accomplishments reflect the credibility and potential of their scientific expertise, particularly in the selective targeting of misfolded proteins through monoclonal antibodies. One founding team member previously achieved significant success, as reflected by a $1.2 billion acquisition of their past antibody candidates in 2021.

In summary, Paradox Immunotherapeutics stands at the forefront of combating protein misfolding diseases with a revolutionary antibody therapy approach. The $10 million investment from SymBiosis marks a pivotal moment in advancing their pipeline, aiming to reform the landscape for treating serious, often overlooked medical conditions. With a strong leadership team and a commitment to innovative science, Paradox is poised to make meaningful contributions to the biotechnology field and tackle pressing healthcare challenges. For more information, the public can visit Paradox’s website or follow their updates on LinkedIn.